title: European Medicines Agency initiatives and perspectives on pharmacogenomics.
abstract: Pharmacogenomics, the study of variations of DNA and RNA characteristics as related to drug response, has become an integral part of drug development and pharmacovigilance, as reflected by the incorporation of pharmacogenomic data in EU product information. In this short review article, we describe recent European Medicines Agency initiatives intended to support further the implementation of pharmacogenomics in drug development and surveillance so that patients and the public can benefit from advances in genomic science and technology.
authors.affiliation: European Medicines Agency, 7 Westferry Circus, London, E14 4HB, UK.
authors.forename: Falk
authors.initials: F
authors.lastname: Ehmann
authors.forename: Laura
authors.initials: L
authors.lastname: Caneva
authors.forename: Marisa
authors.initials: M
authors.lastname: Papaluca
mesh_terms: D055808:Drug Discovery / Q000639:trends*; D005060:Europe; D017408:Guidelines as Topic; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*; D060735:Pharmacovigilance
keywords: European Medicines Agency; guidance; pharmacoepigenetics; pharmacogenomics; regulator